NasdaqGS:KRYSBiotechs
A Look At Krystal Biotech (KRYS) Valuation After UK Approval And Exclusivity Win For VYJUVEK
Krystal Biotech (KRYS) is back in focus after the United Kingdom granted marketing authorization for VYJUVEK, the first genetic medicine approved there for dystrophic epidermolysis bullosa, with orphan status and potential 12-year exclusivity.
See our latest analysis for Krystal Biotech.
At a latest share price of US$299.45, Krystal Biotech has pulled back over the past week but still shows a 30 day share price return of 9.88% and a 1 year total shareholder return of 139.46% relating to...